121 related articles for article (PubMed ID: 7129740)
1. The effects of early treatment, lead time and length bias on the mortality experienced by cases detected by screening.
Morrison AS
Int J Epidemiol; 1982 Sep; 11(3):261-7. PubMed ID: 7129740
[TBL] [Abstract][Full Text] [Related]
2. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties.
Duffy SW; Tabár L; Chen HH; Holmqvist M; Yen MF; Abdsalah S; Epstein B; Frodis E; Ljungberg E; Hedborg-Melander C; Sundbom A; Tholin M; Wiege M; Akerlund A; Wu HM; Tung TS; Chiu YH; Chiu CP; Huang CC; Smith RA; Rosén M; Stenbeck M; Holmberg L
Cancer; 2002 Aug; 95(3):458-69. PubMed ID: 12209737
[TBL] [Abstract][Full Text] [Related]
3. A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer.
Moss SM; Summerley ME; Thomas BT; Ellman R; Chamberlain JO
J Epidemiol Community Health; 1992 Aug; 46(4):362-4. PubMed ID: 1431707
[TBL] [Abstract][Full Text] [Related]
4. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
5. Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases.
Xu JL; Prorok PC
Stat Med; 1995 Dec; 14(24):2715-25. PubMed ID: 8619110
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the survival of cancer cases detected by screening.
Walter SD; Stitt LW
Stat Med; 1987 Dec; 6(8):885-900. PubMed ID: 3438615
[TBL] [Abstract][Full Text] [Related]
7. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
8. Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected.
Kafadar K; Prorok PC
Stat Med; 2009 Jul; 28(16):2116-46. PubMed ID: 19424959
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic and socio-economic factors in screen-detected and symptomatic cases of breast cancer.
Garvican L; Littlejohns P
Public Health; 1998 Jan; 112(1):15-20. PubMed ID: 9490883
[TBL] [Abstract][Full Text] [Related]
10. Further evidence of benefits of a (non-randomised) breast cancer screening programme: the DOM project.
Collette HJ; de Waard F; Rombach JJ; Collette C; Day NE
J Epidemiol Community Health; 1992 Aug; 46(4):382-6. PubMed ID: 1431712
[TBL] [Abstract][Full Text] [Related]
11. Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials.
Kafadar K; Prorok PC
Stat Med; 2003 Jan; 22(1):83-111. PubMed ID: 12486753
[TBL] [Abstract][Full Text] [Related]
12. Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69.
Chiarelli AM; Edwards SA; Sheppard AJ; Mirea L; Chong N; Paszat L; Shumak RS; Oʼmalley FP;
Eur J Cancer Prev; 2012 Nov; 21(6):499-506. PubMed ID: 22273849
[TBL] [Abstract][Full Text] [Related]
13. Implementation of screening as a public health policy: issues in design and evaluation.
Hakama M; Pukkala E; Söderman B; Day N
J Med Screen; 1999; 6(4):209-16. PubMed ID: 10693068
[TBL] [Abstract][Full Text] [Related]
14. Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies.
Abrahamsson L; Isheden G; Czene K; Humphreys K
Stat Methods Med Res; 2020 Feb; 29(2):374-395. PubMed ID: 30854935
[TBL] [Abstract][Full Text] [Related]
15. Predicted long-term mortality reduction associated with the second round of breast screening in East Anglia.
McCann J; Duffy S; Day N;
Br J Cancer; 2001 Feb; 84(3):423-8. PubMed ID: 11161411
[TBL] [Abstract][Full Text] [Related]
16. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data.
Swedish Organised Service Screening Evaluation Group
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):45-51. PubMed ID: 16434585
[TBL] [Abstract][Full Text] [Related]
17. Benefit-to-harm ratio of the Danish breast cancer screening programme.
Beau AB; Lynge E; Njor SH; Vejborg I; Lophaven SN
Int J Cancer; 2017 Aug; 141(3):512-518. PubMed ID: 28470685
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
